MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
0.8469
-0.0039
-0.46%
After Hours: 0.8477 +0.0008 +0.09% 18:32 04/02 EDT
OPEN
0.8393
PREV CLOSE
0.8508
HIGH
0.8700
LOW
0.8120
VOLUME
704.06K
TURNOVER
--
52 WEEK HIGH
7.29
52 WEEK LOW
0.6400
MARKET CAP
83.04M
P/E (TTM)
-1.0625
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATYR last week (0323-0327)?
Weekly Report · 3d ago
Weekly Report: what happened at ATYR last week (0316-0320)?
Weekly Report · 03/23 09:10
Weekly Report: what happened at ATYR last week (0309-0313)?
Weekly Report · 03/16 09:10
aTyr Pharma Inc. Announces Annual Stockholders Meeting Notice
Reuters · 03/12 20:03
Weekly Report: what happened at ATYR last week (0302-0306)?
Weekly Report · 03/09 09:10
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
TipRanks · 03/09 08:16
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
TipRanks · 03/07 06:00
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Immatics (IMTX) and aTyr Pharma (ATYR)
TipRanks · 03/06 13:50
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.